NasdaqGS - Nasdaq Real Time Price USD

Replimune Group, Inc. (REPL)

Compare
11.44 -0.09 (-0.82%)
As of 10:47 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Philip Astley-Sparke F.S.A. Executive Chairman 960.52k -- 1971
Ms. Emily Luisa Hill Chief Financial Officer 593.05k -- 1980
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. Chief Medical Officer 668.69k -- 1967
Dr. Sushil Patel Ph.D. CEO & Director 665.05k -- 1971
Dr. Robert Coffin Ph.D. Founder, Chief Scientist & Director 785.89k -- 1965
Mr. Andrew Schwendenman Chief Accounting Officer & Treasurer -- -- 1976
Mr. Christopher Sarchi Chief Commercial Officer -- -- 1969
Mr. Paul Bullock Chief Manufacturing Officer & Framingham Site Head -- -- --

Replimune Group, Inc.

500 Unicorn Park Drive
Suite 303
Woburn, MA 01801
United States
781 222 9600 https://www.replimune.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
331

Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Replimune Group, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 5, 2024 at 1:30 PM UTC - November 11, 2024 at 1:30 PM UTC

Replimune Group, Inc. Earnings Date

Recent Events

October 7, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

September 5, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 13, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

August 8, 2024 at 12:00 AM UTC

S-3: Offering Registrations

July 19, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

July 10, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

June 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 3, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 16, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

Related Tickers